Argo Biopharma Presents Updated Phase II HAE Therapeutic Results

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma) has presented updated results from its ongoing Phase II clinical trials for BW-20805, a small interfering RNA (siRNA) therapeutic candidate for Hereditary Angioedema (HAE).

The findings were shared in an oral presentation during the Bradykinin Symposium 2026, specifically within a session dedicated to Hereditary Angioedema. The symposium took place on September 4, 2026, with locations in Shanghai and New York.

BW-20805 is designed by Argo Biopharma to target the underlying mechanisms of HAE by reducing the production of specific proteins that trigger disease attacks. The Phase II study aimed to assess the safety, tolerability, and efficacy of the therapeutic in patients diagnosed with HAE.

Argo Biopharma operates as a clinical-stage biopharmaceutical company specializing in siRNA therapeutics, with a focus on developing treatments for rare diseases. HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling.

The presentation of these updated Phase II results offers further insight into the therapeutic potential of BW-20805 as a treatment option for individuals affected by HAE.